HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

2,2-dimethylpropionic acid 3- (2- chloro- 6- methylaminopurin- 9- yl)- 2- (2,2- dimethylpropionyloxymethyl)propyl ester

a P2Y12 receptor antagonist
Also Known As:
MRS 2395; MRS-2395; MRS2395
Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Yao, Ming: 2 articles (08/2014 - 10/2012)
2. Lian, Qingquan: 1 article (08/2014)
3. Liu, Mingjuan: 1 article (08/2014)
4. Xu, Shijie: 1 article (08/2014)
5. Wang, Hanqi: 1 article (08/2014)
6. Xu, Longsheng: 1 article (08/2014)
7. Ni, Huadong: 1 article (08/2014)
8. Zhou, Xu-yan: 1 article (10/2012)
9. Ni, Hua-dong: 1 article (10/2012)
10. Huang, Bing: 1 article (10/2012)

Related Diseases

1. Pain (Aches)
03/01/2010 - "MRS2365 and MRS2395 had a profound, while BBG had a mild effect on inflammatory pain, with a following rank order of mED values: MRS2395 > MRS2365 > BBG. "
10/23/2012 - "These results demonstrate rat bone cancer pain could partially relieved after intrathecal injection of P2Y12 receptor inhibitor MRS2395 through inhibiting the phosphorylation of p38MAPK in spinal dorsal horn."
08/26/2014 - "To explore the roles of P2Y12 receptor (P2Y12R) in bone cancer pain by observing the changes of inflammatory cytokines (IL-1β, IL-6) after intrathecal injection (i.t.) of P2Y12R antagonist MRS2395. "
03/01/2010 - "The rank order of mED values in acute pain was the following: MRS2365 > MRS2395 > NF449 > NF023 > UDP = UTP > PPADS. "
03/01/2010 - "The effect of the wide spectrum P2 receptor antagonist PPADS, the selective P2X7 receptor antagonist Brilliant Blue G (BBG), the P2X1 receptor antagonist (4,4',4'',4-[carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium salt (NF449) and (8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic acid, hexasodium salt (NF023), the P2Y12 receptor antagonist (2,2-dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propylester (MRS2395), the selective P2Y1 receptor agonist ([[(1R,2R,3S,4R,5S)-4-[6-amino-2-(methylthio)-9H-purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphoric acid mono ester trisodium salt (MRS2365), the P2Y2/P2Y4 agonist uridine-5'-triphosphate (UTP), and the P2Y4/P2Y6 agonist uridine-5'-diphosphate (UDP) were examined on mechanical allodynia in the Seltzer model of neuropathic pain, on acute thermal nociception, and on the inflammatory pain and oedema induced by complete Freund's adjuvant (CFA). "
2. Bone Neoplasms (Bone Cancer)
3. Hyperalgesia
4. Neuralgia (Stump Neuralgia)
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. Purinergic P2X7 Receptors
2. Purinergic P2X1 Receptors
3. Purinergic P2Y1 Receptors
4. Cytokines
5. Uridine Triphosphate (UTP)
6. Uridine Diphosphate (UDP)
7. Uridine
8. Freund's Adjuvant
9. (N)-methanocarba-2MeSADP
10. 4,4,',4'',4'''- (carbonylbis(imino- 5,1,3- benzenetriylbis(carbonylimino)))tetrakis(benzene- 1,3- disulfonate)

Related Therapies and Procedures

1. Spinal Injections